Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.

Hirasawa A, Zama T, Akahane T, Nomura H, Kataoka F, Saito K, Okubo K, Tominaga E, Makita K, Susumu N, Kosaki K, Tanigawara Y, Aoki D.

J Hum Genet. 2013 Dec;58(12):794-8. doi: 10.1038/jhg.2013.105. Erratum in: J Hum Genet. 2013 Dec;58(12):825.

PMID:
24088669
2.

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L.

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x.

PMID:
23686699
3.

Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.

Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L.

Med Oncol. 2013;30(3):630. doi: 10.1007/s12032-013-0630-8.

PMID:
23783485
4.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.

Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP.

Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60. doi: 10.1007/s00280-014-2382-3. Review.

PMID:
24448639
5.

Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.

Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR.

World J Gastroenterol. 2013 Jun 28;19(24):3899-903. doi: 10.3748/wjg.v19.i24.3899.

6.

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K.

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z.

PMID:
19390945
7.

[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].

Onoue M, Inui K.

Gan To Kagaku Ryoho. 2008 Jul;35(7):1080-5. Japanese.

PMID:
18633245
8.

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV.

J Clin Pharmacol. 2007 Jan;47(1):78-86.

PMID:
17192505
9.

Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

Sai K, Saito Y, Sakamoto H, Shirao K, Kurose K, Saeki M, Ozawa S, Kaniwa N, Hirohashi S, Saijo N, Sawada J, Yoshida T.

Cancer Lett. 2008 Mar 18;261(2):165-71.

PMID:
18082937
10.

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M.

Br J Cancer. 2004 Aug 16;91(4):678-82.

11.
12.

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y.

Cancer Sci. 2006 Nov;97(11):1255-9.

13.

[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].

Li H, Huang H, Liu JH.

Zhonghua Fu Chan Ke Za Zhi. 2011 Dec;46(12):888-91. Chinese.

PMID:
22333276
14.

Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.

Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M, Kimura M, Minami S, Utsuki H, Yamazaki T, Suzuki T, Tsuji D, Hayashi H, Itoh K.

Tohoku J Exp Med. 2013;229(2):107-14.

15.

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer. 2008 May 1;112(9):1932-40. doi: 10.1002/cncr.23370.

16.

The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.

Sugiyama T, Hirose T, Kusumoto S, Shirai T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Adachi M.

Oncol Res. 2010;18(7):337-42.

PMID:
20377135
17.

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.

Hu ZY, Yu Q, Zhao YS.

Eur J Cancer. 2010 Jul;46(10):1856-65. doi: 10.1016/j.ejca.2010.02.049. Review.

PMID:
20335017
18.

UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

Biason P, Masier S, Toffoli G.

J Chemother. 2008 Apr;20(2):158-65. Review.

PMID:
18467239
19.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N.

Pharmacogenet Genomics. 2007 Jul;17(7):497-504.

PMID:
17558305
20.

[Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].

Teruya T, Nakachi A, Shimabukuro N, Toritsuka D, Azuma Y, Hanashiro K, Nishiki T, Ota M, Shimabuku M, Shiroma H.

Gan To Kagaku Ryoho. 2015 May;42(5):585-9. Japanese.

PMID:
25981652
Items per page

Supplemental Content

Support Center